The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?
While early 2023 saw COVID-19 finally fading away, other global crises continued throughout the year (Russia-Ukraine invasion) or were newly created (Israel-Hamas conflict). In short, the socioeconomic environment remained turbulent.
Also, high interest rates continued to trouble biotech companies and their investors, as reflected in the XBI being down 6%...
As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.
Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.
AI-powered bandages monitor wounds, deliver therapies, and detect complications, offering faster healing and personalized care for improved patient outcomes.
Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.
Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.
![[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space](https://web.insights.norstella-labs.com/resizer/v2/G3M6E2FVDNOJPCEXELJNOIKH64.jpg?smart=true&auth=b5d5c6477bcbd6c122699f47191cbafe560695783f500a6e7b10c4d270965bdc&width=400&height=225)
